journal article·2017-10-03Open access

Nano-liposome-based target toxicity machine: an alternative/complementary approach in atopic diseases

Behzad Mansoori, Ali Mohammadi, Neda Shajari, Sadaf Davudian, Shima Salehi, Behzad Baradaran

Abstract

Despite using lots of progression in hypersensitivity, it is not yet a cure. Current treatment for allergy focuses on two approaches, including treats only the symptoms of allergy by utilizing drugs and the other is desensitization therapy (immunotherapy), which involves administration of specific allergens. The main obstacle to hypersensitivity permanent treatment is the IgE producing subclass of B-lymphocytes which is the source of IgE- producing in hypersensitive patients. Removal of these lymphocytes causes noticeable reduction in the levels of IgE and allergic responses significantly. In this paper, we proposed a novel complementary approach, which we have called the "nano-liposomes-based target toxicity machine (NBTTM)", which controls hypersensitivity by removing the IgE producing B-lymphocytes. In this regard, our proposed nano-liposomes (pollen allergens/Aptamer/SCFV/MIP loaded lipid bilayer enclosing toxin interior) will be able to bind to any IgE markers in the lymphatic circulation. The nano-liposomes will bind to the IgE + atopic B cells and cause cell death by internalizing into B cells.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Allergic Rhinitis and Sensitization · Food Allergy and Anaphylaxis Research · Asthma and respiratory diseases

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran;

Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran;

Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

References (35)

Show source-provided references
1. 10.1016/S0165-2478(97)86342-010.1016/S0165-2478(97)86342-0 ↗
2. 10.1016/j.addr.2012.09.03710.1016/j.addr.2012.09.037 ↗
3. 10.1002/jsscb.1981.38016030510.1002/jsscb.1981.380160305 ↗
4. 10.1016/j.jaci.2011.11.00610.1016/j.jaci.2011.11.006 ↗
5. 10.1038/mtna.2012.2810.1038/mtna.2012.28 ↗
6. 10.1016/j.jaci.2013.01.04910.1016/j.jaci.2013.01.049 ↗
7. 10.1002/jssc.20120078410.1002/jssc.201200784 ↗
8. 10.3109/21691401.2014.95363310.3109/21691401.2014.953633 ↗
9. 10.1016/S0021-9673(01)93763-X10.1016/S0021-9673(01)93763-X ↗
10. 10.1016/0022-1759(81)90109-510.1016/0022-1759(81)90109-5 ↗
11. 10.1016/j.jaci.2005.09.03910.1016/j.jaci.2005.09.039 ↗
12. 10.1016/j.jaci.2014.09.01210.1016/j.jaci.2014.09.012 ↗
13. 10.1016/j.coi.2013.10.00710.1016/j.coi.2013.10.007 ↗
14. 10.1007/978-3-642-31609-8_1110.1007/978-3-642-31609-8_11 ↗
15. 10.1038/nri329810.1038/nri3298 ↗
16. 10.1006/meth.1999.084110.1006/meth.1999.0841 ↗
17. 10.1016/0005-2736(95)00138-S10.1016/0005-2736(95)00138-S ↗
18. 10.1038/aps.2013.8810.1038/aps.2013.88 ↗
19. Huang A · J Biol Chem · 1980 · 255 · 801510.1016/S0021-9258(19)70595-X ↗
20. 10.1111/j.1398-9995.2011.02589.x10.1111/j.1398-9995.2011.02589.x ↗
21. 10.1021/bi962148u10.1021/bi962148u ↗
22. 10.1038/nri193410.1038/nri1934 ↗
23. Lessof MH. · 2012
24. 10.1021/ac050802i10.1021/ac050802i ↗
25. 10.3109/1071754950903136510.3109/10717549509031365 ↗
26. 10.1016/j.ijpharm.2005.10.00510.1016/j.ijpharm.2005.10.005 ↗
27. Rahman M · Artif Cells Nanomed Biotechnol. 44: · 2016 · 1
28. 10.1208/s12248-012-9330-010.1208/s12248-012-9330-0 ↗
29. 10.4172/2155-6113.100030410.4172/2155-6113.1000304 ↗
30. 10.1016/j.iac.2015.08.00610.1016/j.iac.2015.08.006 ↗
31. 10.1016/j.jaci.2014.12.190610.1016/j.jaci.2014.12.1906 ↗
32. Susan S. · Methods Mol Med · 2000 · 25 · 51
33. 10.1016/S0065-2776(04)82003-010.1016/S0065-2776(04)82003-0 ↗
34. 10.2353/ajpath.2007.06127910.2353/ajpath.2007.061279 ↗
35. 10.1111/j.1365-2222.2006.02340.x10.1111/j.1365-2222.2006.02340.x ↗